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1521-6934/© 2017 Published by Elsevier Ltd.Hormonal treatment of abnormal uterine bleeding (AUB), espe-
cially bleeding related to endometrial causes (AUB-E), ovulatory
dysfunction (AUB-O) and coagulopathy (AUB-C), and to some
extent, uterine leiomyomas and adenomyosis, has become the
first-line evidence-based management strategy during recent
years. Hormonal treatment of heavy menstrual bleeding (HMB) is
also endorsed as the first line of treatment in several international
guidelines.
In the present article, we review the efficacy of the commonly used
and widely available hormonal treatments of AUB-O, AUB-E and
AUB-C. The therapies include combined hormonal contraceptives,
progestin-only preparations, and intrauterine release of levonor-
gestrel through the levonorgestrel-releasing intrauterine system.
In addition, we make practical recommendations for patient
management.
We also review some of the current guidelines and their recom-
mendations concerning the treatment of HMB. Finally, the effects
of hormonal treatment on the overall management of AUB and its
effects on the health care system and specialist training are
discussed.
© 2017 Published by Elsevier Ltd.Helsinki University Hospital, P.O. Box 610, 00029-HUS, Helsinki, Finland.
(O. Heikinheimo).
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Combined hormonal contraceptives
Ethinylestradiol-containing preparations
The use of combined oral contraceptives (COCs) reduces uterine bleeding in healthy women by
approximately 40% during 6 months of use [1]. The endometrial mechanism(s) of action of COCs in
reducing menstrual flow involve the downregulation of endometrial estrogen receptors resulting in
atrophic glandular endometrium because of prolonged progestin exposure of the endometrium [2].
The therapeutic use of ethinylestradiol-containing COCs in the treatment of heavy menstrual
bleeding (HMB) has been compared to that of the levonorgestrel (LNG)-releasing intrauterine system
(LNG-IUS) in recent studies from Canada [3] and Egypt [4]. In the Egyptian study, use of a COC con-
taining 30 mg of EE and 150 mg of LNG resulted in a decrease of 35% in the measured blood loss during 1
year of follow-up assessed by the alkaline hematin method [4]. The Canadian study, using a COC
containing 20 mg of EE and 1 mg of northisterone acetate, reported a 68% decrease in menstrual blood
loss during 1 year of use [3].
In addition, treatment of HMB using a vaginal ring (Nuva Ring®, MSD/Merck) releasing 15 mg of EE
and 120 mg of etonogestrel vs. long-cycle northisterone acetate (5 mg t.i.d. on cycle days 5e26) was
assessed in an Egyptian study [5]. Both treatments were equally effective in reducing the menstrual
blood loss during the 3-month study with 69% vs. 70% decline in PBAC score, respectively. However, use
of the vaginal ring was significantly better tolerated and had a high (77%) continuation rate [5].
Estradiol-containing preparations
Novel combined contraceptive preparations containing estradiol instead of ethinylestradiol are also
efficacious in treating HMB.Withdrawal bleeding was absent in approximately 20% of the womenwith
the use of estradiol valerate- and dienogest-containing COC [6] and in up to 30% of the womenwith the
use of 17b-estradiol- and nomegestrole acetate-containing COC [7].
In a large placebo-controlled multicentre trial performed in women suffering from documented
HMB, estradiol valerate- and dienogest-containing COC reduced menstrual bleeding by approximately
60% in 6 months of use [8]. Treatment of HMB is also an approved indication for the commercially
available preparation containing estradiol and dienogest. However, COCs containing estradiol vs.
ethinylestradiol or the possible role of the progestin component of COCs have not been tested in
randomized trials.
A commonly used but little-researched strategy is the long-cycle use of combined hormonal con-
traceptives (CHCs) [9]. Although reduction of menstrual bleeding is often cited a clinical advantage, no
randomized trials have assessed the efficacy of long-cycle CHCs in the treatment of HMB.
Table 1 summarizes the overall reduction in menstrual flow with the use of different hormonal
preparations in women with HMB. The reduction in HMB and the length of the various studies ac-
cording to the type of hormonal treatment are highlighted in Figure 1.
Progestins
Cyclic luteal-phase administration of progestin remained a widely used but little-researched
treatment strategy for HMB for several decades. However, scientific studies comparing luteal (i.e.,
10e14 days/mo) with NSAIDs, tranexamic acid, or LNG-IUS have revealed that luteal-phase progestin
has minimal or no effect on the bleeding and is no longer considered a valid treatment option for HMB
[10].
Extended (i.e., cycle days 5-26) use of progestin with 5 mg of NETA three times a day (t.i.d.) was
compared to the intrauterine release of LNG by LNG-IUS in a study by Irvine et al. [11]. Three months of
extended use of NETA reduced the measured blood loss by 87% among womenwith documented HMB.
However, satisfaction with the extended NETA treatment was poor, and only few women (i.e., 22%)
chose to continue the treatment. Similarly, comparison of EE- and etonogestrel-releasing vaginal ring
and extended use of NETA in HMB treatment revealed significantly lower acceptance and continuation
rate of the NETA [5]. Thus, extended use of progestin provides an effective but poorly tolerated systemic
therapy for HMB.
Table 1









Ethinylestradiol-containing COC 35% 12 mo Before and after Shabaan et al., 2011 [4]
Estradiol valerate- and dienogest-
containing COC
60% 7 mo Before and after Fraser et al., 2012 [8]
Progestin-only preparations








Kaunitz et al., 2010 [24]
Extended cycle progestin (i.e., NETA
5 mg t.i.d. on cycle days 5-26)
87% 3 mo Before and after Irvine et al., 1998 [11]
LNG-IUS 86% e 97% 6e12 mo Before and after Andersson and Rybo, 1990 [14]
Milsom et al., 1991 [15]
Reid & Virtanen-Kari 2005 [35]
Shabaan et al., 2011 [4]
Kaunitz et al., 2010 [24]
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Studies on the intrauterine release of LNG for contraception through intrauterine device began in
the 1970s [12]. When testing the first experimental LNG-IUS, it soon became evident that uterine
bleeding is strongly reduced with LNG-IUS use [13]. The therapeutic potential of the LNG-IUS was
rapidly tested in women suffering from HMB by Andersson and Rybo [14] and Milsom et al. [15]. A
mean reduction of 82% in uterine bleedingwas observed during the first 3months of LNG-IUS use. Thus
a suggestion that the LNG-IUS can be an important alternative to oral medication and hysterectomy in
the treatment of HMB was made in the early 1990s.The LNG-IUS in the treatment of heavy menstrual bleeding
Mechanism of action
Themechanism(s) bywhich intrauterine release of LNG reduces uterine bleeding have been studied
intensively since the 1970s. In the first histological studies, a strong suppression of the endometrial
epithelium and glands was seen with LNG-IUS use. However, the stroma was marked by intense
decidual reaction, which is typical of early pregnancy [16]. In addition, the LNG-exposed endometrial
stroma expressed similar markers of decidualization as that of first trimester of pregnancy [17].
The mediators of sex steroid action, namely steroid receptors and steroid-metabolizing enzymes, in
endometrium are altered with LNGeIUS use. There is a marked downregulation of both epithelial and
stromal expression of estrogen and progesterone receptors [18]. An increased expression of endo-
metrial 17b-hydroxysteroid dehydrogenase type 2, which is responsible for converting estradiol into
estrone, has been described [19]. These alterations possibly reduce the proliferative effects of estradiol
on endometrium and explain in part the endometrial suppression and reduced bleeding with LNG-IUS
use.
In addition, stromal expression of insulin-like growth factor-binding protein-1 is upregulated with
LNG-IUS use. This may result into the sequesteration of endometrial insulin-like growth factor-1 (IGF-
1), thereby reducing the proliferative effects of IGF-1. This may be one of the mechanisms resulting in
the suppression of endometrial epithelium with LNG-IUS use [20].
The LNG-IUS also has an effect on the endometrial levels of various hemostatic factors. Specifically,
endometrial content of u-PAR and PAI-1 and 2 was significantly increased after 1 month of LNG-IUS use
[21]. However, the effects of LNG-IUS on angiogenic growth factor(s) are less clear. Both an increase and
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described with LNG-IUS use [22,23].
LNG-IUS in comparison to medical treatments in the treatment of HMB
A landmark paper by Kaunitz et al. [24] compared the use of LNG-IUS and cyclic oral progestin
(10 mgMPA/day on cycle days 16-25) among womenwith documented HMB. Treatment with LNG-IUS
resulted in a mean reduction of 71% of measured monthly blood loss in comparison to 22% among
women randomized for cyclic MPA; the treatment outcomewas judged successful in 85% of thewomen
randomized to LNG-IUS and in 22% of the women randomized to cyclic progestin.
Gupta et al. [25] compared LNG-IUS with conventional medical therapies (tranexamic acid,
mefenamic acid, and combined preparations of estrogen and progestin or progestin-only) in theFig. 1. Mean reductions in menstrual bleeding (measured by pictorial Blood loss Assessment Chart score) according to the duration
of treatment in women suffering from AUB-E and being treated with a. LNG-IUS b. CHCs c. Oral progestins  21 days/cycle Please
note the different time scales in the three panels. Modified with permission from Bitzer et al. [31].
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study, eligible women were randomized for receiving LNG-IUS and conventional medical therapy to
be decided by the treating physician. The primary outcome measuredpatient-reported Menorrhagia
Multi-attribute Scaledincreased in both groups. However, the increase was significantly greater in
the LNG-IUS group. In addition, the quality of life indices and continuation of method use at 2 years
(64% vs. 38%, respectively) were significantly higher in the LNG-IUS group than in the usual-care
group.
LNG-IUS in comparison to surgical treatments in the treatment of HMB
Endometrial ablation
Kaunitz et al. [26] compared LNG-IUSwith endometrial ablation therapy in the treatment of HMB in
ameta-analysis of six randomized trials. The reduction inmenstrual bleedingwas similar following the
two treatment strategies up to 2 years of follow-up. Similarly, improvement in the quality of life did not
differ between the treatment groups. Both treatment strategies were not associated with major
complications.
Hysterectomy
Although the idea of using LNG-IUS instead of hysterectomy in the treatment of HMB was intro-
duced in 1990 [14], the first prospective study concerning the use of LNG-IUS instead of hysterectomy
was published in 1998 [27]. In the study by L€ahteenm€aki et al. [27], altogether 56 women scheduled for
hysterectomy for the treatment of excessive uterine bleeding were randomized to continue their
current treatment (i.e., surgery) or the insertion of LNG-IUS. The primary outcome measure was the
rate of hysterectomies cancelled by 6months. Of thewomen randomized to the LNG-IUS, 64% cancelled
the operation compared to only 14% in the control group (p<0.001). Thus, the authors concluded that
LNG-IUS is a good alternative to hysterectomy in the treatment of menorrhagia and should be
considered before invasive treatment [27].
A randomized Finnish multicentre study compared the efficacy and long-term outcomes of LNG-
IUS and hysterectomy among women referred to hospital for hysterectomy because of HMB [28].
Altogether 236 women consented for the study and were randomized to receive treatment for HMB
with LNG-IUS or hysterectomy. At 1 year of follow-up, 20% and 91% of thewomen randomized to LNG-
IUS and hysterectomy, respectively, had undergone hysterectomy. At 5 years, the corresponding
figures were 42% and 93% [29]. The various outcomes of health-related quality of life (HRQL) were
similar between the two groups. Nevertheless, the overall health-related costs were significantly
lower among women randomized to the LNG-IUS (mean 2817 vs. 4660 USD). Thus, the authors
concluded that by providing improvement in HRQL at relatively low cost, the LNG-IUS may offer
wider availability of choices for the patient and may decrease costs due to interventions involving
surgery [29].
A recently updated Cochrane review assessed altogether 15 parallel-group research studies
comparing medical therapy (oral medications or the LNG-IUS)and surgical treatment (endometrial
resection or hysterectomy) for HMB [30]. There were altogether 11 studies that evaluated the LNG-IUS.
The review concluded that following surgical treatment, there was more objective control of bleeding
at 1 year. However, the quality of life at 5 or 10 years did not differ between women assigned to the
LNG-IUS and surgical treatments. Concerning adverse events of complications, surgical treatment was
associatedwith an increased risk of surgical complications (such as organ perforation), whereas the use
of LNG-IUS had a risk of insufficient therapeutic effect (i.e., on-going bleeding) or associated subjective
hormonal side effects. The Cochrane review concluded that although surgery provides an effective
long-term therapeutic effect, the LNG-IUS provides a better alternative to surgery for most women
suffering from HMB.
A recent comprehensive review on the medical management of HMB by Bitzer et al. [31] proposed a
treatment algorithm for women suffering from abnormal uterine bleeding (AUB) because of endo-
metrial causes (AUB-E) or coagulopathies (AUB-C). The algorithm (Fig. 2) takes into account women's
different wishes (such as wish for pregnancy) and preferences (such as acceptance of intrauterine
treatment).
Fig. 2. Algorithm on the medical treatment of AUB-E or AUB-C in various clinical circumstances. The most effective treatment in
terms of reduction of HMB is indicated by the number 1 and the second-most effective by the number 2. (a) please note the possible
contraindications to CHCs; (b) and (c) nonhormonal options, do not act as contraceptives; (c) may be the first choice in cases of
associated dysmenorrhea; (d) treatment of HMB is an official indication for the preparation containing estradiol valerate and
dienogest; and (e) may not function as a contraceptive. Modified with permission from Bitzer et al. [31].
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There are several international guidelines on the treatment of AUB/HMB (Table 2). In addition,
several Cochrane reviews have assessed the efficacy of hormonal treatment in the treatment of AUBTable 2
National guidelines on the treatment of AUB/HMB. Summary of the recommendations concerning in hormonal treatment. All
guidelines included promote the use of medical therapy as the first-line treatment strategy.
Canada Finland France UK/NICE USA/ACOG**
Type of AUB
covered
AUB HMB HMB HMB AUB-O
Order of efficacy (if recommended)
COC ‘reduce effectively’ ‘recommended’ 3. 2. 2.
Luteal-phase
progestin
‘not effective’ ‘not effective’ NA ‘not to be used’ 3.
Extended-cycle
progestin
‘reduce effectively’ ‘recommended’ 4. 3.
DMPA ‘reduce effectively’ ‘not recommended’ NA 3.
LNG-IUS ‘reduce effectively’ ‘recommended’* 1. 1. 1.
Tranexamic
acid
‘can be used’ ‘recommended’ 2. 2. 2.
NSAID ‘can be used’ ‘recommended’ 5. 2. 3.










* LNG-IUS should be tried before the surgical treatment of HMB is undertaken.
** The American College of Obstetricians and Gynecologists.
Fig. 3. Annual number of hysterectomies and the number of Mirena®-units (Bayer AG, Turku, Finland) sold in Finland in 1997e2012.
Fig. 4. Publication of the key articles on the use of LNG-IUS in the treatment of HMB and the national guideline on the treatment of
HBM vs. the annual number of hysterectomies in Finland in 1997e2012.
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LNG-IUS as the most effective hormonal treatment for HMB (Fig. 3).
The effect of systematic research and treatment guidelines on clinical practice
Research studies assessing the efficacy of hormonal treatment of AUB often recruit patients ac-
cording to the etiology of the bleeding disturbance. However, in daily clinical practice, this is often
difficult and treatments are sought according to suspected or most likely etiology.
Since the introduction of medical treatment of HMB and treatment guidelines, several countries
have witnessed a marked decline in the rate of hysterectomy. For example, in Australia and Italy, the
rate of hysterectomy has decreased by approximately 40% in the recent decades [33,34].
Figure 4 highlights the annual number of hysterectomies performed for benign diseases in Finland.
In addition, publications of major Finnish research studies comparing the treatment of AUB by LNG-IUS
with hysterectomy and publication of the national guideline on the evaluation and treatment of MHD
are shown in Figure 4. Similarly, the rate of annual number of hysterectomies has declined approxi-
mately 40%, from 10,000 annual hysterectomies in the late 1990s to approximately 6000 during the
2010s.
Thus, medical treatment of HMB and its active promotion have significantly reduced the need of
surgical treatment of AUB. These changes are likely to continue with the availability of novel medi-
cations to control uterine diseases and bleeding symptoms. These changes are also increasingly re-
flected in the curriculum of specialist training programs in obstetrics and gynecology.
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 LNG-IUS is the most effective and long-lasting option for the hormonal treatment of HMB.
 CHCs, especially those containing estradiol valerate, are also effective in reducing menstrual
bleeding by approximately 60%.
 Promotion of hormonal treatment and publication of national and international guidelines on
the treatment of HMB have reduced the need for hysterectomy in several countries.
Research agenda
 Novel hormonal mediations such as selective progesterone receptor modulators in HMB
 The impact of conservative treatment of AUB and its active promotion on the need for
specialist training and training curricula.Summary
Hormonal therapy by CHCs, long-cycle progestins, or intrauterine release of LNG through LNG-IUS
has become the first-line treatment for HMB. Several research studies have shown that the LNG-IUS
provides the most efficacious and long-lasting option for the hormonal treatment of HMB. The men-
strual blood flow is reduced by approximately 95% during the first year of use among women suffering
O. Heikinheimo, I. Fraser / Best Practice & Research Clinical Obstetrics and Gynaecology 40 (2017) 111e120 119from HMB. Moreover, the LNG-IUS provides an effective therapy for at least up to 5 years. CHCs,
especially those containing estradiol valerate, are also efficacious and reduce the volume of menstrual
flow in women with documented HMB by approximately 60%.
Medical treatment of HMB has been endorsed as the first line of treatment for HMB by several
national and international practice guidelines on HMB during the last decade. Treatment by LNG-IUS
has been ranked as the most effective by all guidelines recommending therapies according to their
efficacy. Such endorsements are rapidly altering the treatment strategies of HMB, resulting in reduced
need of surgical treatments including hysterectomy. Decreasing need of surgical treatment is currently
also affecting the requirements and curriculum of specialist trainings in obstetrics and gynecology and
the structure of health care systems.References
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